Section Arrow
GYRE.NASDAQ
- Gyre Therapeutics
Quotes are at least 15-min delayed:2024/10/31 20:00 EDT
Last
 14.5
-0.21 (-1.43%)
Day High 
14.79 
Prev. Close
14.71 
1-M High
15.42 
Volume 
47.60K 
Bid
14.3
Ask
14.44
Day Low
14.3 
Open
14.62 
1-M Low
11.7 
Market Cap 
1.37B 
Currency USD 
P/E 57.89 
%Yield 46.94 
10-SMA 14.25 
20-SMA 13.66 
50-SMA 13.3 
52-W High 30.4 
52-W Low 6.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.01/-4.53
Enterprise Value
1.37B
Balance Sheet
Book Value Per Share
0.65
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
113.45M
Operating Revenue Per Share
1.09
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 20:00 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.